| 000 | 01700 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513231856.0 | ||
| 264 | 0 | _c20010222 | |
| 008 | 200102s 0 0 eng d | ||
| 022 | _a0022-1899 | ||
| 024 | 7 |
_a10.1086/317936 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSobel, J D | |
| 245 | 0 | 0 |
_aThe evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. _h[electronic resource] |
| 260 |
_bThe Journal of infectious diseases _cJan 2001 |
||
| 300 |
_a286-93 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xmicrobiology |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntifungal Agents _xpharmacology |
| 650 | 0 | 4 |
_aCandida _xclassification |
| 650 | 0 | 4 |
_aCandida albicans _xdrug effects |
| 650 | 0 | 4 |
_aCandidiasis, Oral _xdrug therapy |
| 650 | 0 | 4 |
_aCandidiasis, Vulvovaginal _xdrug therapy |
| 650 | 0 | 4 | _aDrug Resistance, Microbial |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluconazole _xpharmacology |
| 650 | 0 | 4 | _aHIV Seronegativity |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 |
_aOropharynx _xmicrobiology |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aVagina _xmicrobiology |
| 700 | 1 | _aOhmit, S E | |
| 700 | 1 | _aSchuman, P | |
| 700 | 1 | _aKlein, R S | |
| 700 | 1 | _aMayer, K | |
| 700 | 1 | _aDuerr, A | |
| 700 | 1 | _aVazquez, J A | |
| 700 | 1 | _aRampalo, A | |
| 773 | 0 |
_tThe Journal of infectious diseases _gvol. 183 _gno. 2 _gp. 286-93 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1086/317936 _zAvailable from publisher's website |
| 999 |
_c11142173 _d11142173 |
||